Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens
Cancer Cytopathology · 2024
DOI: 10.1002/cncy.22901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, 2024. Verfasst von Deepak Donthi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Gastrointestinal Neoplasms, Repressor Proteins, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: The University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Background
Trichorhinophalangeal syndrome 1 (TRPS1) expression in primary breast and other solid tumors has been investigated but its role as a marker in metastatic tumors is unclear. The objective of this study was to evaluate the sensitivity and specificity of TRPS1 as a breast cancer immunomarker in metastatic tumors that originated from breast, Müllerian, lung, gastrointestinal (GI), and pancreatic primary tumors with cell blocks from fine‐needle aspiration (FNA) and effusion specimens.
Methods
Cell blocks were immunostained with anti‐TRPS1 monoclonal antibody (clone EPR16171). Histochemical scores (H scores) (proportion × intensity; range, 0–300) were assigned; H scores of ≥10 were considered positive. Overall, 160 specimens were examined, including 127 FNAs (35 breast, 25 Müllerian, 36 lung, and 31 GI and pancreatic carcinomas) and 33 effusion specimens (18 breast, 12 Müllerian, one lung, and two GI carcinomas).
Results
TRPS1 was positive in 51 of 53 (96%) metastatic breast carcinomas and in 28 of 107 (26.2%) nonbreast metastatic tumors. Metastatic breast carcinoma showed the highest mean H score of 247.35, compared to 45.36 in Müllerian, 8.4 in lung, and 5.88 in GI tumors. The sensitivity and specificity of TRPS1 for identifying a breast origin in metastatic tumors was 96.22% and 72.89%, respectively.
Conclusions
Despite high overall sensitivity, TRPS1 showed lower specificity as a breast immunomarker because of its expression in nonbreast tumors. The mean H score in nonbreast tumors was significantly lower than in metastatic breast tumors. It is important to recognize the broad range of expression of TRPS1 in metastatic breast and nonbreast tumors to avoid an incorrect determination of a metastatic tumor’s organ of origin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Deepak Donthi, Qiong Gan, Savitri Krishnamurthy
Förderung
- The University of Texas MD Anderson Cancer Center
Zitieren
APA
Donthi, D., Gan, Q., Ding, Q. Q., & Krishnamurthy, S. (2024). Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens. Cancer Cytopathology. https://doi.org/10.1002/cncy.22901
Vancouver
Donthi D, Gan Q, Ding QQ, Krishnamurthy S. Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens. Cancer Cytopathology. 2024. doi:10.1002/cncy.22901
BibTeX
@article{Donthi2024,
author = {Donthi, Deepak and Gan, Qiong and Ding, Qing Qing and Krishnamurthy, Savitri},
title = {Trichorhinophalangeal syndrome 1 expression in breast and nonbreast metastases from Müllerian, lung, gastrointestinal tract, and pancreatic primary tumors by immunohistochemistry with cytology cell block specimens},
journal = {Cancer Cytopathology},
year = {2024},
doi = {10.1002/cncy.22901}
}
EUVIMED